Anzeige
Mehr »
Dienstag, 20.01.2026 - Börsentäglich über 12.000 News
98,7% Goldausbeute ohne Cyanid - kommt jetzt der Milliarden-Deal?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DE2T | ISIN: CA71719L1067 | Ticker-Symbol:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PHARMALA BIOTECH HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
PHARMALA BIOTECH HOLDINGS INC 5-Tage-Chart

Aktuelle News zur PHARMALA BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.01.Pharmala Biotech Holdings Inc: Pharmala to supply LaNeo for Ostfold clinical research2
08.01.PharmAla Biotech: PharmAla To Supply Østfold Hospital Trust with LaNeo MDMA for Clinical Research1
24.12.25Pharmala Biotech Holdings Inc: Pharmala Biotech files fiscal 2025, Q1 2026 financials4
PHARMALA BIOTECH Aktie jetzt für 0€ handeln
24.12.25PharmAla Biotech: PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements226TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and...
► Artikel lesen
16.12.25Pharmala Biotech Holdings Inc: Pharmala Biotech Australia hires CDMO for manufacturing1
11.12.25Pharmala Biotech Holdings Inc: Pharmala completes release testing on LaNeo capsules1
10.12.25PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules1
04.11.25Pharmala Biotech Holdings Inc: Pharmala Biotech files final prospectus1
03.11.25PharmAla Biotech: PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital217TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and...
► Artikel lesen
09.10.25Pharmala Biotech Holdings Inc: Pharmala launches Nexus chain-of-care portal1
08.10.25PharmAla Biotech: PharmAla Launches Nexus Portal for MDMA Prescribers and Therapists3
02.10.25Pharmala Biotech Holdings Inc: Pharmala Biotech completes shipment to Johns Hopkins3
02.10.25PharmAla Biotech: PharmAla Completes Shipment of LaNeo MDMA to Johns Hopkins2
26.09.25Pharmala Biotech Holdings Inc: Pharmala enters distribution deal with Veridion3
25.09.25PharmAla Biotech: PharmAla Partners with Veridion Group as Exclusive Distributor in New Zealand1
19.09.25Pharmala Biotech Holdings Inc: Pharmala Biotech files amended preliminary prospectus1
19.09.25PharmAla Biotech: PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus1
08.09.25PharmAla Biotech: PharmAla Completes Import of LaNeo MDMA for US Distribution116TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and...
► Artikel lesen
04.09.25Pharmala Biotech Holdings Inc: Pharmala incorporates Ausi unit for clinical research2
03.09.25PharmAla Biotech: PharmAla Incorporates Australian Entity for Clinical Research1
Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1